Key Takeaways From ITC Analysis of First-Line Dual-IO Treatments in Advanced Melanoma

Panelists discuss how the ITC analysis of first-line dual-IO treatments in advanced melanoma highlights the potential for nivolumab plus relatlimab to offer similar efficacy to nivolumab plus ipilimumab, with a more favorable safety profile, particularly in terms of lower rates of severe immune-related adverse events.

EP: 1.Treatment Decisions in Metastatic Melanoma: Immunotherapy vs Targeted Therapy

EP: 2.Key Takeaways from the RELATIVITY-047 Trial: Managing Advanced Melanoma

EP: 3.Indirect Treatment Comparison: RELATIVITY-047 and CheckMate 067

EP: 4.Dual Immunotherapy IO Treatment and Sequencing Decisions for Melanoma

EP: 5.Insight on Treating Patients With Melanoma With Brain Metastases

EP: 6.Expert Insight on Using Dual-IO Regimens for Melanoma in Real-World Practice

EP: 7.Potential Roles for First-Line Targeted Therapy for Advanced Melanoma

Now Viewing

EP: 8.Key Takeaways From ITC Analysis of First-Line Dual-IO Treatments in Advanced Melanoma

Recent Videos